XANAP: A real‐world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia

BACKGROUND: ROCKET AF and its East Asian subanalysis demonstrated that rivaroxaban was non‐inferior to warfarin for stroke/systemic embolism (SE) prevention in patients with non‐valvular atrial fibrillation (NVAF), with a favorable benefit–risk profile. XANAP investigated the safety and effectivenes...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Young‐Hoon, Shim, Jaemin, Tsai, Chia‐Ti, Wang, Chun‐Chieh, Vilela, Gilbert, Muengtaweepongsa, Sombat, Kurniawan, Mohammad, Maskon, Oteh, Li Fern, Hsu, Nguyen, Thang Huy, Thanachartwet, Thititat, Sim, Kenneth, Camm, A. John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111488/
https://www.ncbi.nlm.nih.gov/pubmed/30167013
http://dx.doi.org/10.1002/joa3.12073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111488/
https://www.ncbi.nlm.nih.gov/pubmed/30167013
http://dx.doi.org/10.1002/joa3.12073

Ejemplares similares